Skip to main content
Premium Trial:

Request an Annual Quote

Helix Partners With Illumina Accelerator to Support Consumer-Focused DNA Tech

NEW YORK (GenomeWeb) – Helix announced today that it has partnered with Illumina Accelerator to provide support to new companies developing DNA-based products for the consumer market.

Illumina launched its accelerator program in 2014 to assist startups and early-stage companies working on next-generation sequencing applications. Over six-month cycles, it provides participants with funding, instrumentation, technological expertise, and lab space, among other things.

Through the partnership, Helix will now offer resources to certain Illumina Accelerator startups that are working on consumer-focused DNA products. These resources include expertise in next-generation sequencing and bioinformatics, applied genomics, software and product development, regulatory affairs, quality assurance, consumer marketing, and business development.

"By working with Helix during our seventh funding cycle, select startups will have unparalleled access to Helix's commercial market expertise and sequencing platform for their consumer applications," Mostafa Ronaghi, Illumina's chief technology officer and accelerator program cofounder, said in a statement.

"Through our collaboration with Illumina Accelerator, we hope to provide breakthrough startups with the resources, infrastructure, and support to transform their ideas into compelling consumer applications and services that make genomics relevant and accessible to every person based on their unique interests," Helix CEO Robin Thurston added in the statement.

Last month, Helix launched an online marketplace of consumer genomics applications including ones for fitness, ancestry, and disease risk. The app store includes products developed by a variety of different companies.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.